ENERGIZE THE FIGHT.
BREAKING NEWS: FDA APPROVES TK2D THERAPY
The U.S. Food and Drug Administration (FDA) has approved UCB’s Kygevvi (doxecitine and doxribtimine) to treat the mitochondrial disease TK2d. “It’s hard to put into words what today’s decision means for patients living with TK2d,” said UMDF President and CEO Kristen Clifford. READ MORE >>
Our Mito Champions
Need to Connect with Us?
Call the Support Line: (888) 900-6486
Ask the Mito Doc – December 2025
Ask the Mito Doc - December 2025: Wrapping Up 2025 with Our Mito Docs All answers today are based on personal experience of the participants. As always, please consult your personal physician prior to taking any action.Bnech to Bedside - Special Edition: Clinical...
Bench to Bedside – Clinical Trial Updates
Bench to Bedside - Special Edition: Clinical Trial Updates All answers today are based on personal experience of the participants. As always, please consult your personal physician prior to taking any action.Bnech to Bedside - Special Edition: Clinical Trial...
December 2025 Newsletter: NY Jets Bring Mito Awareness, New Research Grants, Clinical Trials Updates, and more
Signup to receive the UMDF newsletter in your email monthly at umdf.org/newsletter-signup.





